Illumina, Inc. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: DNA sequencing and genomics.
The next scheduled catalyst is Next quarterly earnings (projected) on October 22, 2026, a projected date rather than a confirmed one. There are 4 upcoming events on record.
Illumina, Inc. generates cash from operations, so a burn-based runway figure does not apply.
Across 13 concluded trials, 92% reached completion rather than being terminated or withdrawn.
Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.